Antibody-based immunological therapies (Q41642431)

6 October 2017

1 reference

title

Antibody-based immunological therapies (English)

1 reference

6 October 2017

1 reference

Scott AM

1

1 reference

PubMed ID

9368782

6 October 2017

Welt S

series ordinal

2

1 reference

6 October 2017

1 October 1997

1 reference

Current Opinion in Immunology

6 October 2017

1 reference

6 October 2017

9

1 reference

6 October 2017

5

1 reference

6 October 2017

717-722

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

6 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Immunotherapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Clinical promise of tumour immunology

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Design and production of novel tetravalent bispecific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Specificity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Tumor Therapy by Immune Recruitment with Bispecific Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

The epidermal growth factor receptor as a target for therapy in breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2897%2980054-4

7 January 2021

10.1016/S0952-7915(97)80054-4

Identifiers

DOI

1 reference

6 October 2017

1 reference

PubMed ID

9368782